Common Stock, Par Value $0.0001 Per Share
- Symbol
- JAGX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 1.01, 3.02, 8.01, 9.01 · 8-K
Jaguar Health, Inc.
JAGXNASDAQEQUITYCurrent
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, on November 12, 2025, Jaguar Health, Inc. (the “Company”) issued and sold to Streeterville Capital, LLC (“Streeterville”) a secured promissory note in the original principal amount of $10,810,000 (as amended, the “2025 Note”) pursuant to that certain Note Purchase Agreement between the same parties dated as of the even date.…
Company context
Jaguar was founded in San Francisco, California, as a Delaware corporation on June 6, 2013 (“inception”). The Company was a majority-owned subsidiary of Napo until the close of the Company’s initial public offering on May 18, 2015. The Company was formed to develop and commercialize first-in-class prescription and non-prescription products for companion animals. On July 31, 2017, Jaguar completed a merger with Napo pursuant to the Agreement and Plan of Merger dated March 31, 2017, by and among Jaguar, Napo, Napo Acquisition Corporation (“Merger Sub”), and Napo’s representative (the “Merger Agreement”). In accordance with the terms of the Merger Agreement, upon the completion of the merger, Merger Sub merged with and into Napo, with Napo surviving as the wholly owned subsidiary (the “Merger” or “Napo Merger”). Immediately following the Merger, Jaguar changed its name from “Jaguar Animal Health, Inc.” to “Jaguar Health, Inc.” Napo now operates as a wholly owned subsidiary of Jaguar focused on human health, including the ongoing development of crofelemer and commercialization of Mytesi.
Current securities
Recent company filings
- 424B5 filingSep 24, 2026
- Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other EventsSep 21, 2026
- PRE 14A filingSep 18, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesSep 15, 2026
- Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureSep 15, 2026
Registered securities in this filing
Jaguar Health, Inc. · 8-K · Filed 2026-09-24
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement.
As previously disclosed, on November 12, 2025, Jaguar Health, Inc. (the “Company”) issued and sold to Streeterville Capital, LLC (“Streeterville”) a secured promissory note in the original principal amount of $10,810,000 (as amended, the “2025 Note”) pursuant to that certain Note Purchase Agreement between the same parties dated as of the even date.
On September 23, 2026, the Company entered into privately negotiated exchange agreements with Streeterville (collectively, the “2025 Note Exchange Agreements”), pursuant to which the Company issued an aggregate of 547,898 shares (the “2025 Note Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”) to Streeterville in exchange for a $5,049,909.26 reduction in the outstanding balance of the 2025 Note (the “2025 Note Exchange Transaction”).
The 2025 Note Exchange Agreements include representations, warranties, and covenants customary for a transaction of this type.
The foregoing description of the 2025 Note Exchange Agreements does not purport to be complete and is qualified in its entirety by the 2025 Note Exchange Agreements, the form of which is filed herewith as Exhibit 10.1 and incorporated herein by reference.
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item 3.02 Unregistered Sales of Equity Securities.
The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02 in its entirety. The 2025 Note Exchange Shares were issued in reliance on the exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”).
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
As of September 23, 2026, the Company had approximately 1,281,867 shares of Common Stock issued and outstanding.